RETA Stock News

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

Reata Pharma (NASDAQ: RETA) shares jumped over 25% on February 28, after the clinical-stage biopharmaceutical company reported worse-than-expected fourth-quarter results. However, Reata revealed … The post Reata Pharma Gains 25% Despite Q4 Miss appeared first on Smarter Analyst .

https://www.investing.com/news/stock-market-news/reata-pharmaceuticals-shares-rise-22-after-fourth-quarter-earnings-2774262

Gainers Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group, Inc. (NASDAQ: REGI ) shares jumped 38.7% to $60.75 after Chevron Corp (NYSE: CVX ) announced an agreement to acquire the company. IntriCon Corporation (NASDAQ: IIN ) gained 37.3% to $23.91 after the company agreed to be acquired by an affiliate of Altaris Capital Partners for $241 million. IntriCon also posted Q4 EPS of $0.23. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) climbed 30.5% to $2.01 after gaining around 8% on Friday. First Horizon Corporation (NYSE: FHN ) shares climbed 30.4% to $23.80 after TD announced acquisition of the company for $25 per share in cash. Imperial Petroleum Inc. (NASDAQ: IMPP ) shares rose 26% to $2.6450 after jumping around 34% on Friday. Everbridge, Inc. (NASDAQ: EVBG ) gained 23% to $37.67. Lifeway Foods, Inc. (NASDAQ: LWAY ) surged 20% to $6.60. Azure Power Global Limited (NYSE: AZRE ) gained 19.9% to $18.76.

Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.

Shares of Reata Pharmaceuticals (RETA) are continuing to struggle in premarket trading after announcing Q4 2021 results that missed on the top line.

Reata Pharmaceuticals Inc.'s (RETA) CEO Warren Huff on Q4 2021 Results - Earnings Call Transcript

Reata Pharmaceuticals (NASDAQ: RETA ) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Reata Pharmaceuticals beat estimated earnings by 31.17%, reporting an EPS of $-1.59 versus … Full story available on Benzinga.com

Reata Pharmaceuticals press release (RETA): Q4 Non-GAAP EPS of -$1.59 beats by $0.34.Revenue of $0.93M (-70.9% Y/Y) misses by $0.83M.At December 31, 2021, the company cash and…

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter and full year ended on December 31, 2021 and provided an update on the Company’s business operations and clinical development programs. “We are making important progress in our efforts to advance omaveloxolone for the treatment of patients with Friedreich’s ataxia (‘FA’) including r

The FDA has issued a Complete Response Letter (CRL) regarding Reata Pharmaceuticals Inc''s (NASDAQ: RETA ) application seeking approval for bardoxolone methyl for chronic kidney disease (CKD) caused by Alport syndrome. The agency concluded that it does not believe the submitted data demonstrates that bardoxolone effectively slows the loss of … Full story available on Benzinga.com

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th